3B Future Health Fund
Venture capitalMonaco · Pre-Seed–Late Stage · 12 people tracked
Find your way into 3B Future Health Fund
269 people in our graph share verified history with the 3B Future Health Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
3B Future Health Fund backs early-stage and clinical-development-stage healthcare companies with potential first-in-class assets, revolutionary science, experienced management and strong investor syndicates. It concentrates entirely on healthcare, prioritizing oncology and rare diseases with high unmet patient need, and is drug-modality agnostic. Initial investments are typically made at Series A, though sometimes earlier. The 10-year fund plans a diversified portfolio of 10-15 companies, investing up to $12 million per company, seeking board positions and reserving capital for follow-on rounds. Holdings are expected to last five to eight years, or less if value-inflection exits arise. Targets are based in the US, Europe and Israel.
Source: firm website, verified Aug 3, 2026.
Team · 12 people
from the firm's website & public directories
What they invest in
from 18 of 22 portfolio companiesBiotech ×17Healthtech ×11Medical Devices ×8Digital Health ×4AI & Machine Learning ×3Deep Tech ×3Cleantech ×1Crypto & Web3 ×1
HQs:United States×7Italy×2France×1United Kingdom×1Sweden×1
Investments · 22 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12023 · 12022 · 12020 · 12018 · 16 dated
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investorsAlly Bridge GroupDecheng CapitalVivo CapitalAvoro VenturesOrbiMed
Gain Therapeutics develops therapeutics using allosteric innovation approaches.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesBethesda, US
BoardMarianne Bjordal(Director)Lorenzo Leoni(Director)Khalid Islam(Director)Jeffrey Riley(Director)Eric I. Richman(Executive Officer, Director)
Co-investorsTiVenture SA
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investorsIndustrifondenNovo HoldingsPureos BioventuresSound Bioventures
Greenbone Ortho develops orthopedic medical products and constantly pursues clinical innovation and new applications.
BiotechCleantechHealthtechMedical DevicesNew MaterialsFaenza, IT
Anna Tampieri(Chairman & Director)Saverio Gellini(Chief Executive Officer & Director)inAndrea Cha(Chief Operating Officer)inVanessa Bonomi(Chief Quality Regulatory Officer)inPaolo Sala(Chief Financial Officer)inSusanna Salvagno(Chief Medical & Scientific Officer)in
Co-investorsItalian Angels for GrowthCDP Venture Capital
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more
BiotechPhiladelphia, US
William Hinshaw(Executive Officer, Director)inJeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)
BoardErez Chimovits(Director)inGiovanni Mariggi(Director)inMatthew Foy(Director)
Board seatRoberto De Ponti· per SEC Form D · $122.6M raise · filed Aug 2023
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatRoberto De Ponti· per SEC Form D
Co-investorsCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersARCH Venture PartnersBering CapitalIntervest+3 more
Co-investorsBioMedPartnersVI Partners
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investorsCTI Life Sciences Fund L.P.
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investorsAlbionVCEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology FundBioGeneration Ventures
BiotechPlymouth Meeting, US
Niranjan Y. Sardesai(Executive Officer, Director)inLaurent Humeau(Director)James Eadie(Director)Samuel Broder(Director)Sangwoo Lee(Director)Casey Cunningham(Director)
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkefM VenturesVI PartnersXGEN Venture
Co-investorsCDP Venture CapitalClaris VenturesElysia CapitalItalian Angels for Growth
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Kevan E. Clemens(Director)Thomas C. Reynolds(Director)
Co-investorsAisling CapitalGSRNew Enterprise Associates (NEA)Vivo Capital
Neophore develops a small-molecule therapeutic that transiently inhibits DNA Mismatch Repair (MMR) to convert MMR-proficient tumours into an MMR-deficient state, making them responsive to cancer immunotherapy.
AI & Machine LearningBiotechLongevity
Co-investorsAstellas Venture Management LLCClaris VenturesNeva Sgr.
On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.
BiotechHealthtechMedical Devices
Bill Peters(President, Chief Executive Officer, and Board Member)inRod MacLeod(Chief Financial Officer)inTommy Lee(Senior Vice President of Clinical Operations)inCatherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)inScott Huennekens(Executive Chairperson)in
Co-investorsCerity Partners VenturesElevate VenturesH.I.G. CapitalH.I.G. HealthBridge Partners
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
BiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inLuis A. Diaz, Jr.(Executive Officer, Director, Promoter)Sam Angiuoli(Executive Officer)inSian Jones(Executive Officer)inLisa Kann(Executive Officer)inAnthony Newton(Executive Officer)
Co-investorsCatalio Capital Management, LPCo-Win VenturesNew Enterprise Associates (NEA)Windham Capital PartnersVensana Capital
QuantuMDx develops point-of-care molecular diagnostics platforms and assays for detecting infectious diseases including sexually transmitted infections, antimicrobial resistance, respiratory viruses, and other pathogens.
Digital HealthHealthtechMedical DevicesNewcastle upon Tyne, GB
Elaine Warburton(Co-Founder and former CEO)
Co-investorsAdjuvoDEFTA Partners
Roca Therapeutics develops first-in-class small molecule therapies for patients with neovascular retinal diseases.
BiotechHealthtechMedical DevicesNice, FR
Obtained U.S.
Co-investorsAMR Action Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioAadi BioscienceNASDAQ: WHWKGain TherapeuticsNASDAQ: GANXUtility Therapeuticsacq. by Alembic Pharmaceuticals
Portfolio news
latest coverage across their companiesPersonal Genome Diagnostics · chiefhealthcareexecutive.com · Nov 24, 2025
MEI Pharma · investing.com · Jul 18, 2025
Aadi Bioscience · qz.com · Mar 28, 2025
iOnctura · prnewswire.com · Mar 17, 2025
Frequently asked questions
- How many investments has 3B Future Health Fund made?
- 3B Future Health Fund has 21 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does 3B Future Health Fund invest at?
- 3B Future Health Fund invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What is 3B Future Health Fund's typical check size?
- 3B Future Health Fund typically writes checks of $12M.
- What sectors does 3B Future Health Fund focus on?
- 3B Future Health Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is 3B Future Health Fund located?
- 3B Future Health Fund is headquartered in Monaco, MC.
- Who does 3B Future Health Fund co-invest with?
- 3B Future Health Fund most often shares deals with Claris Ventures, CDP Venture Capital, Italian Angels for Growth, among 44 tracked co-investors.
Co-investors · 5
Claris Ventures is an early-stage investor that makes equity investments in biopharma companies with strong scientific evidence and a clear vision.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Seroba is a Dublin-based life sciences venture capital firm investing in early-stage biotech and medtech companies developing new therapeutics and medical devices.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Seventure Partners is a European venture capital firm, founded in 1997 and a subsidiary of Natixis Investment Managers, investing in digital technologies and life sciences companies with strong growth potential.
Firms observed investing alongside 3B Future Health Fund, from public investor directories. Shared companies are the overlap with 3B Future Health Fund's recorded portfolio.
Similar investors
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.